The Impact of a Multivisceral Resection and Adjuvant Therapy in Locally Advanced Colon Cancer.


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 12 2017
accepted: 31 08 2018
pubmed: 5 10 2018
medline: 17 4 2020
entrez: 5 10 2018
Statut: ppublish

Résumé

Multivisceral resection for locally advanced colon cancer is mandatory to achieve complete tumor resection. We aimed to determine if local multivisceral resections (LMR) for pT4 and pT3 tumors impact perioperative and long-term oncological outcomes. All stage II or III colon cancer patients who had surgery between 2004 and 2014 were identified. We analyzed patients with non-multivisceral resections (NMR) for pT4 tumors vs. pT4-LMR. In addition, outcomes were compared to both NMR and LMR pT3 patients. LMR was performed in 55 (29.7%) of all patients with pT4 tumors and in 48 (8.9%) of all patients with pT3 tumors. The most commonly involved areas of extension were the abdominal wall and the small intestine. Transverse colon cancer was correlated with LMR. Morbidity rates were comparable between NMR and LMR, with the exception of higher rates of blood transfusion and postoperative ileus. Over one third of all pT4-NMR patients developed recurrent disease, which was higher compared to all other groups. Subsequently, overall and disease-specific survival, as well as disease-free survival (DFS), was worse for pT4-NMR, even after adjustment for pTN-staging, adjuvant therapy, and R0 resection. Furthermore, when analyzing only curative resections, radial margin < 1 cm along with nodal disease was independent predictor for worse DFS. Long-term outcomes were comparable between pT4-LMR and pT3 patients. Multivisceral resection for locally advanced colon cancer preserves long-term oncological outcomes without increased postoperative morbidity. Moreover, LMR in pT3 tumors does not contribute to postoperative morbidity. Our study underlines the feasibility and importance of performing LMR when locally advanced cancer is suspected.

Sections du résumé

BACKGROUND
Multivisceral resection for locally advanced colon cancer is mandatory to achieve complete tumor resection. We aimed to determine if local multivisceral resections (LMR) for pT4 and pT3 tumors impact perioperative and long-term oncological outcomes.
METHODS
All stage II or III colon cancer patients who had surgery between 2004 and 2014 were identified. We analyzed patients with non-multivisceral resections (NMR) for pT4 tumors vs. pT4-LMR. In addition, outcomes were compared to both NMR and LMR pT3 patients.
RESULTS
LMR was performed in 55 (29.7%) of all patients with pT4 tumors and in 48 (8.9%) of all patients with pT3 tumors. The most commonly involved areas of extension were the abdominal wall and the small intestine. Transverse colon cancer was correlated with LMR. Morbidity rates were comparable between NMR and LMR, with the exception of higher rates of blood transfusion and postoperative ileus. Over one third of all pT4-NMR patients developed recurrent disease, which was higher compared to all other groups. Subsequently, overall and disease-specific survival, as well as disease-free survival (DFS), was worse for pT4-NMR, even after adjustment for pTN-staging, adjuvant therapy, and R0 resection. Furthermore, when analyzing only curative resections, radial margin < 1 cm along with nodal disease was independent predictor for worse DFS. Long-term outcomes were comparable between pT4-LMR and pT3 patients.
CONCLUSIONS
Multivisceral resection for locally advanced colon cancer preserves long-term oncological outcomes without increased postoperative morbidity. Moreover, LMR in pT3 tumors does not contribute to postoperative morbidity. Our study underlines the feasibility and importance of performing LMR when locally advanced cancer is suspected.

Identifiants

pubmed: 30284199
doi: 10.1007/s11605-018-3962-z
pii: 10.1007/s11605-018-3962-z
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

357-366

Références

J Natl Cancer Inst. 2006 Oct 18;98(20):1474-81
pubmed: 17047196
Arch Surg. 2004 Jan;139(1):39-42
pubmed: 14718273
JAMA Surg. 2015 Sep;150(9):890-8
pubmed: 26132363
Cell Biochem Biophys. 2011 Jan;59(1):1-6
pubmed: 20740326
Dis Colon Rectum. 2004 Dec;47(12):2055-63
pubmed: 15657654
Lancet. 1995 Apr 15;345(8955):939-44
pubmed: 7715291
Dis Colon Rectum. 2009 Aug;52(8):1381-6
pubmed: 19617748
Ann Intern Med. 1995 Mar 1;122(5):321-6
pubmed: 7847642
Langenbecks Arch Surg. 1999 Apr;384(2):194-9
pubmed: 10328174
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Dis Colon Rectum. 2005 May;48(5):897-909
pubmed: 15785892
World J Surg. 2010 Sep;34(9):2177-84
pubmed: 20512493
Ann Surg Oncol. 2013 Sep;20(9):2929-36
pubmed: 23666095
Colorectal Dis. 2015 Nov;17(11):943-53
pubmed: 25808496
Cancer. 2004 Mar 1;100(5):958-67
pubmed: 14983491
Dis Colon Rectum. 2012 Aug;55(8):831-43
pubmed: 22810468
World J Surg. 2008 Jul;32(7):1495-500
pubmed: 18305994
Lancet. 2000 Sep 16;356(9234):968-74
pubmed: 11041397
Langenbecks Arch Surg. 2014 Jan;399(1):33-40
pubmed: 24249035
Dis Colon Rectum. 2000 Jan;43(1):83-91
pubmed: 10813129
Br J Surg. 2011 Aug;98(8):1171-8
pubmed: 21560120
Am J Surg. 2013 Dec;206(6):1024-32; discussion 1032-3
pubmed: 24296103
Clin Colorectal Cancer. 2014 Mar;13(1):68-72
pubmed: 24503112
Surg Gynecol Obstet. 1992 Jan;174(1):27-32
pubmed: 1729745
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
pubmed: 11309435

Auteurs

Lieve G J Leijssen (LGJ)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Anne M Dinaux (AM)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

R Amri (R)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Hiroko Kunitake (H)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Liliana G Bordeianou (LG)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

David L Berger (DL)

Department of General and Gastrointestinal Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. dberger@mgh.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH